Alemtuzumab/cladribineAutoimmune thyroid disorder and alopecia areata universalis: 2 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1898卷 / 1期

关键词：

D O I：

10.1007/s40278-022-11622-9

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：29 / 29

相关论文

共 50 条

[31] CiclosporinAlopecia areata: 2 case reports
Reactions Weekly, 2006, 1093 (1) : 10 - 11
[32] TozinameranAlopecia areata: 2 case reports
Reactions Weekly, 2023, 1960 (1) : 407 - 407
[33] Alemtuzumab/immunosuppressantsPost transplant lymphoproliferative disorder: 15 case reports
Reactions Weekly, 2018, 1724 (1) : 22 - 22
[34] Alemtuzumab/prednisoloneVarious toxicities: 2 case reports
Reactions Weekly, 2022, 1922 (1) : 33 - 33
[35] Alemtuzumab/vedolizumabHypersensitivity reactions: 2 case reports
Reactions Weekly, 2018, 1726 (1) : 24 - 24
[36] BusulfanPermanent alopecia: 2 case reports
Reactions Weekly, 2005, 1059 (1) : 8 - 9
[37] MethotrexateLeucopenia and alopecia: 2 case reports
Reactions Weekly, 2013, 1458 (1) : 30 - 30
[38] Peginterferon-α-2b/ribavirinAlopecia areata universalis: case report
Reactions Weekly, 2014, 1492 (1) : 35 - 35
[39] AdalimumabPsoriasiform alopecia: 2 case reports
Reactions Weekly, 2010, 1291 (1) : 5 - 5
[40] AdalimumabAlopecia areata and fatigue: 2 case reports
Reactions Weekly, 2016, 1585 (1) : 14 - 14

← 1 2 3 4 5 →